A new randomized clinical trial found that men with localized, intermediate‑risk prostate cancer recovered faster and ...

The Society of Interventional Radiology (SIR) announced that the CAPTAIN randomized clinical trial found that men with ...

A new randomized clinical trial found that men with localized, intermediate‑risk prostate cancer recovered faster and experienced less short‑term impact on their daily lives when treated with ...

Two enzymes from the protein disulphide isomerase (PDI) family enable prostate cancer cells to grow, survive, and resist treatment. This discovery, however, could be taken as an advantage to improve ...

Much of the challenge in developing cancer therapies is determining methods to improve the effectiveness of the immune system’s ability to identify and kill cancer cells. While therapies like CAR T ...

Prostate cancer affects one in eight men in the U.S. over their lifetime, which is the same rate as women and breast cancer.

Doctors have long looked to the hormone testosterone as a piece of the prostate cancer puzzle. The man on the other end was J. Bruce Hunsicker, an Akron-based lawyer with prostate cancer who had ...

SBRT Delays Systemic Therapy in Oligometastatic Cancers For patients with oligometastatic cancers, particularly kidney or prostate, stereotactic body radiotherapy may frequently delay the need for ...

New findings highlight Telomir-1’s impact on CASP8 and GSTP1, two critical genes that regulate cell death and glutathione-based detoxification pathways often disrupted in cancer. MIAMI, FLORIDA / ...

An international group led by researchers from the RIKEN Center for Integrative Medical Sciences (IMS) in Japan has ...